Arbutus Biopharma Corporation ABUS Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $160.72M+580% | -$33.5M+20.8% | -$42.28M+22.1% | -$54.25M+29.1% | -$76.57M-9.5% | ||
| $44K-87.9% | $363K-47.0% | $685K-32.2% | $1.01M-25.5% | $1.36M-1.8% | ||
| $4.75M-31.7% | $6.95M-5.1% | $7.32M-10.9% | $8.22M-22.0% | $10.54M+17.2% | ||
| -$1.44M+4.5% | -$1.5M-114% | -$703K+5.3% | -$742K+22.5% | -$957K-251% | ||
| —— | —— | —— | -$6.62M-272% | $3.84M+241% | ||
| -$1.09M+35.8% | -$1.7M-9.3% | -$1.55M+8.5% | -$1.7M+40.8% | -$2.87M-24.8% | ||
| -$558K-0.2% | -$557K-10.5% | -$504K+0.2% | -$505K-9.3% | -$462K-7.4% | ||
| —— | —— | —— | -$11.03M-473% | -$1.93M-41.9% | ||
| -$1.92M-4.9% | -$1.83M-167% | $2.72M-2.7% | $2.79M+1.8% | $2.74M+4.5% | ||
| —— | —— | —— | —— | —— | ||
| -$34.36M+13.3% | -$39.64M+12.4% | -$45.27M+24.8% | -$60.19M-2.1% | -$58.95M+9.1% | ||
| $119.15M-14.9% | $140.06M-11.2% | $157.71M+7.5% | $146.74M-2.7% | $150.83M+6.6% | ||
| $125.21M-19.4% | $155.28M-17.5% | $188.13M+7.4% | $175.2M+1.0% | $173.52M+5.4% | ||
| —— | —— | —— | —— | —— | ||
| $14.42M+160% | $5.54M+4.1% | $5.32M-13.0% | $6.12M-20.3% | $7.68M+2.7% | ||
| $14.56M+154% | $5.72M+4.0% | $5.5M-14.5% | $6.43M-78.8% | $30.35M-41.6% | ||
| —— | —— | —— | —— | —— | ||
| -$13.37M+27.0% | -$18.32M-94.1% | -$9.44M— | —— | —— | ||
| $1.99M-15.5% | $2.35M-17.6% | $2.85M-13.4% | $3.29M-0.2% | $3.3M+5.3% | ||
| -$1.92M-4.9% | -$1.83M-167% | $2.72M-2.7% | $2.79M+1.8% | $2.74M+4.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$11.03M-473% | -$1.93M-41.9% | ||
| -$1.09M+35.8% | -$1.7M-9.3% | -$1.55M+8.5% | -$1.7M+40.8% | -$2.87M-24.8% | ||
| $84K-11.6% | $95K-11.2% | $107K-4.5% | $112K-5.9% | $119K-6.3% | ||
| $1.22M-18.0% | $1.48M-14.7% | $1.74M-15.7% | $2.06M-2.1% | $2.11M-6.4% | ||
| —— | —— | —— | —— | $2.98M+1,683% | ||
| $125.21M-19.4% | $155.28M-17.5% | $188.13M+7.4% | $175.2M+1.0% | $173.52M+5.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | -$39.64M+12.6% | -$45.36M+24.8% | -$60.28M-2.1% | -$59.03M+9.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Arbutus Biopharma Corporation generate?
- Arbutus Biopharma Corporation (ABUS) generated -$34.4M in operating cash flow over the trailing twelve months.
- Where does Arbutus Biopharma Corporation's cash flow data come from?
- Every line is extracted from Arbutus Biopharma Corporation's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
